glp 1 gip mounjaro Dual GLP-1/GIP Agonist | Tirzepatide | Obesity & T2DM Mx | Harrison's Update(22nd Ed.) Tirzepatide (Mounjaro): A Dual-Action Breakthrough

The autoinjector is one of the fastest emerging drug delivery solutions

There may also be an increase in strategic partnerships and acquisitions as companies look to bolster their portfolios with proven subq GLP-1 assets

A study of almost 2000 people published in February 2021 has shown that a new, once-a-week weight loss injection can help patients with obesity.

Focus on supporting overall health while aiding fat loss

Pharmacovigilance analyses identified disproportionate reporting signals for dyspnoea and asthma-like events, particularly with exenatide, using the reporting odds ratio (ROR 2.14, 95% CI 1.882.43

GLP-1 receptor agonists have shown cardiovascular benefits beyond weight loss, including potential improvements in cholesterol profiles